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P-selectin- and heparanase-dependent antimetastatic activity of
non-anticoagulant heparins
Abstract
Vascular cell adhesion molecules, P- and L-selectins, facilitate metastasis of cancer cells in mice by
mediating interactions with platelets, endothelium, and leukocytes. Heparanase is an endoglycosidase
that degrades heparan sulfate of extracellular matrix, thereby promoting tumor invasion and metastasis.
Heparin is known to efficiently attenuate metastasis in different tumor models. Here we identified
modified, nonanticoagulant species of heparin that specifically inhibit selectin-mediated cell-cell
interactions, heparanase enzymatic activity, or both. We show that selective inhibition of selectin
interactions or heparanase with specific heparin derivatives in mouse models of MC-38 colon carcinoma
and B16-BL6 melanoma attenuates metastasis. Selectin-specific heparin derivatives attenuated
metastasis of MC-38 carcinoma, but heparanase-specific derivatives had no effect, in accordance with
the virtual absence of heparanase activity in these cells. Heparin derivatives had no further effect on
metastasis in mice deficient in P- and L-selectin, indicating that selectins are the primary targets of
heparin antimetastatic activity. Selectin-specific and heparanase-specific derivatives attenuated
metastasis of B16-BL6 melanomas to a similar extent. When mice were injected with a derivative
containing both heparanase and selectin inhibitory activity, no additional attenuation of metastasis could
be observed. Thus, selectin-specific heparin derivatives efficiently attenuated metastasis of both tumor
cell types whereas inhibition of heparanase led to reduction of metastasis only in tumor cells producing
heparanase.
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ABSTRACT Vascular cell adhesion molecules, P- and
L-selectins, facilitate metastasis of cancer cells in mice
by mediating interactions with platelets, endothelium,
and leukocytes. Heparanase is an endoglycosidase that
degrades heparan sulfate of extracellular matrix,
thereby promoting tumor invasion and metastasis. Hep-
arin is known to efficiently attenuate metastasis in
different tumor models. Here we identified modified,
nonanticoagulant species of heparin that specifically
inhibit selectin-mediated cell-cell interactions, hepara-
nase enzymatic activity, or both. We show that selective
inhibition of selectin interactions or heparanase with
specific heparin derivatives in mouse models of MC-38
colon carcinoma and B16-BL6 melanoma attenuates
metastasis. Selectin-specific heparin derivatives attenu-
ated metastasis of MC-38 carcinoma, but heparanase-
specific derivatives had no effect, in accordance with
the virtual absence of heparanase activity in these cells.
Heparin derivatives had no further effect on metastasis
in mice deficient in P- and L-selectin, indicating that
selectins are the primary targets of heparin antimeta-
static activity. Selectin-specific and heparanase-specific
derivatives attenuated metastasis of B16-BL6 melano-
mas to a similar extent. When mice were injected with a
derivative containing both heparanase and selectin in-
hibitory activity, no additional attenuation of metastasis
could be observed. Thus, selectin-specific heparin de-
rivatives efficiently attenuated metastasis of both tumor
cell types whereas inhibition of heparanase led to
reduction of metastasis only in tumor cells producing
heparanase.—Hostettler, N., Naggi, A., Torri, G., Ishai-
Michaeli, R., Casu, B., Vlodavsky, I., Borsig, L. P-
selectin- and heparanase-dependent antimetastatic ac-
tivity of non-anticoagulant heparins. FASEB J. 21,
3562–3572 (2007)
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Heparin and low molecular weight heparin
(LMWH) have been widely used as anticoagulants for
more than 50 years. Cancer patients suffering from
recurrent thrombosis are frequently treated with hepa-
rin and LMWH (1–9). Despite several clinical studies
indicating an effect of heparin and LMWH on prolong-
ing patients’ survival, the anti-neoplastic effect of hep-
arin remains controversial (1–3). Although thrombotic
complications associated with cancer have an adverse
effect on prognosis in all cancer types, patients with
such complications usually die from cancer rather than
fatal thrombosis (10). Thus, the improved survival of
cancer patients treated with heparin or LMWH is likely
due to a direct effect on cancer progression. Based on
these observations, several randomized-controlled trials
were performed recently (5, 6, 8, 9). Although there
was no improvement in survival in patients with an
originally poor prognosis, a subgroup of patients with a
better prognosis demonstrated a statistically significant
increase in survival (5). Similarly, patients with ad-
vanced solid tumor malignancy treated with LMWH
demonstrated an improvement in survival rate (6, 8, 9).
Meanwhile, other studies showed that heparin and
LMWH are not just mere anticoagulants, but rather
complex glycosaminoglycans with several biological
functions (11, 12). Among other biological activities,
heparin and LMWH are known to affect thrombin
generation (10), cause release of tissue factor pathway
inhibitor (TFPI) from endothelial surfaces (13), mod-
ulate growth factor receptor binding and activity (14),
affect angiogenesis (15), inhibit heparanase enzymatic
activity (16), and reduce selectin-mediated interactions
(17, 18). The hypothesis that heparin and LMWH
directly influence cancer progression and metastasis
was further supported by experimental studies in
mouse models (for reviews, see refs. 12, 19, 20).
Heparin and LMWH were shown to attenuate exper-
imental metastasis in several mouse models of carcino-
mas and melanomas (16, 21–24). However, nonantico-
agulant heparins could still efficiently inhibit
metastasis; therefore, anticoagulation is just one activity
of heparin in this process (16, 23, 25, 26). Heparin was
also shown to affect metastasis through inhibition of
heparanase activity (16, 27). The enhanced expression
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of heparanase in mammary adenocarcinomas, lympho-
mas, and melanomas is causally associated with in-
creased invasiveness and metastasis (16, 27, 28). Hepa-
rin or LMWH treatment attenuated metastasis by
inhibition of heparanase in experimental metastasis of
human and rat mammary carcinoma and mouse mela-
noma (27, 29). We and others have reported that
heparin attenuated metastasis in mouse models of
carcinomas and melanomas primarily through inhibi-
tion of selectin interactions (17, 21, 22, 24). Selectins
are vascular cell adhesion molecules promoting initial
leukocyte-endothelial interactions. In addition, P-and
L-selectin are implicated in pathological processes in-
volving inflammation, reperfusion injury, and cancer
(30, 31). The absence of P- and/or L-selectin led to
attenuation of metastasis in mouse models, thus impli-
cating both selectins in cancer metastasis (17, 21, 22,
32). Heparin is a potent inhibitor of P- and L-selectin
(33). Heparin injection shortly before tumor cells was
found to inhibit P-selectin-mediated platelet/tumor
cell interactions; injection of heparin at later time
inhibited metastasis in an L-selectin-dependent manner
(21, 24, 32). Although there is general agreement on
the potential of heparin to attenuate metastasis in
mouse models and to improve prognosis of cancer
patients, the underlying molecular mechanism of hep-
arin action requires further clarification (10, 19, 34).
In the present study the elucidation of heparanase
and selectin contribution to metastasis was analyzed
using modified nonanticoagulant species of heparins.
We previously observed that heparin primarily affected
selectin-dependent interactions with carcinoma cells
(17, 21) whereas the inhibition of heparanase was
shown to attenuate metastasis in mouse melanoma (16,
27). Results from the current study show that, depend-
ing on the cell type, attenuation of metastasis could be
achieved equally well by inhibition of selectin interac-
tions or heparanase enzymatic activity.
MATERIALS AND METHODS
Cell lines and reagents
Mouse colon carcinoma cell line MC-38 stably expressing GFP
MC-38GFP (21) and mouse melanoma cell line B16-BL6 (27)
were grown in DMEM with 4.5 g/L of glucose supplemented
with 10% FCS medium (Invitrogen, Carlsbad, CA, USA).
Human colon carcinoma cells LS180 (ATCC, Manassas, VA,
USA) were grown in MEM media (Invitrogen) supple-
mented with 10% FCS (Invitrogen). All reagents were from
Sigma (St. Louis, MO, USA) unless otherwise stated.
Mice
P-selectin-deficient mice (P-sel/) in a C57BL/6J back-
ground and control wild-type (wt) C57BL/6J mice were
obtained from The Jackson Laboratory (Bar Harbor, ME,
USA). PL-selectin-double-deficient (PL-sel/) mice in a
C57BL/6J background have been described (21).
Heparin derivatives
The reference heparin (H, mol wt 18,000) was a commercial
preparation from pig mucosa (Laboratori Derivati Organici,
Trino Vercellese, Italy). Detailed preparation and character-
ization of all heparin derivatives have been reported, includ-
ing notations (35). The following derivatives were prepared:
1) two extensively 6-O-desulfated heparins, one of which
(6Odes-H, mol wt 20,400) essentially retains the original
content of 2-O-sulfate groups, and the other also partially
(15%) 2-O-desulfated (6Odes,p2Odes-H, mol wt 16,000); 2)
two extensively 2-O-desulfated heparins, one retaining the
original IdoA configuration (2Odes-H IdoA) and the other
(2Odes-H GalA), where the original residues were converted
to l-galacturonic acids; 3) two partially 6-O-sulfated deriva-
tives (516Odes-H and 426Odes-H); 4) N-acetylated heparins
(50NA-H, 58NA-H, 70NA-H, and 100NA-H); 5) a glycol-split
heparin of the RO (reduced oxyheparins) -type RO-H; 6) the
RO, N-acetylated derivatives 50NA-RO.H and 100NA-RO.H;
and 7) fluorescein-labeled RO.H and 100NA-RO.H (prepared
as reported for heparin) (36). All samples were recovered
after desalting by freeze-drying and characterized by NMR
spectroscopy.
Flow cytometry analysis
Selectin ligands expressed on MC-38 and B16-BL6 tumor cells
were analyzed with mouse selectins as described previously
(21). Briefly, cells were detached with PBS containing 2 mM
EDTA for 5 min at 37°C, and washed with Hanks’ balanced
salt solution (HBSS) prior to blocking with 0.5% BSA in
HBSS. Mouse P-selectin chimera was preincubated with a
biotinylated goat-anti-human IgG Ab for 1 h at room temper-
ature (RT) and added to cells for 1 h at 4°C. After a wash,
streptavidin-PE-Cy5 (Becton Dickinson, Mountain View, CA,
USA) was added for another 20 min. Cells were washed with
HBSS and resuspended in HBSS/BSA.
Determination of anti-Xa levels in mouse plasma
Mice were intravenously (i.v.) injected with 150 g of heparin
and its derivatives via the tail vein. Twenty minutes after
injection, blood was collected by cardiac puncture into a
syringe filled with 30 l of 10 mM EDTA in PBS. Samples were
centrifuged twice at 1000 g and the aliquoted plasma was
stored at80°C. Anti-Xa activity was determined as described
previously (24). Briefly, 1.25 l of plasma was added to 155 l
of 25 mM HEPES/159 mM NaCl (pH 7.5) together with
human antithrombin III (3.3 g/well; Enzyme Research
Laboratories, South Bend, IN, USA) and human factor Xa
(0.02 g/well, Enzyme Research Laboratories). Samples were
incubated with 25 g of synthetic factor Xa chromogenic
substrate (Diapharma, Columbus, OH, USA) for 15 min. The
reaction was stopped by addition of 20% acetic acid and
measured at 405 nm using a GENios ELISA reader (Tecan,
Ma¨nnedorf, Switzerland). Plasma anticoagulant activity of the
heparin derivatives was calculated in anti-Xa units/ml in
comparison to a standard curve. All measurements were done
in triplicate and repeated three times with three independent
mouse samples.
Determination of tissue factor pathway inhibitor (TFPI) in
mouse plasma
Plasma samples were dialyzed against 20 mM Tris/Cl, pH 7.4.
Plasma diluted 4-fold was separated on nonreducing 8%
SDS-PAGE gel. Proteins were transferred to a nitrocellulose
membrane and blocked with 5% nonfat milk in TBS (block-
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ing solution), followed by incubation with rabbit anti-mouse
TFPI antiserum (American Diagnostica, Stamford, CT, USA)
at 1:500 dilution in the blocking solution (37). After three
washes, the membrane was incubated with goat anti-rabbit
antibody conjugated to horseradish peroxidase at a 1:10,000
dilution and developed with chemiluminescence Supersignal
(Pierce, Rockford, IL, USA). Lysate of mouse carotid artery
was used as a positive control (37). TFPI signal was captured
by digital camera and analyzed with AIDA Imaging software
(Diana III; Raytest, Straubenhardt, Germany).
Heparanase activity assay
Heparin species were tested for their ability to inhibit hepara-
nase, as described previously (16, 35). Briefly, sulfate-labeled
ECM coating the surface of 35 mm culture dishes was
incubated (4 h, 37°C, pH 6.0) with recombinant human
heparanase (40 ng/ml) in the absence or presence of differ-
ent amounts (0.2–5 g/ml) of each heparin species. The
proteoglycan fragments were separated by gel filtration and
the radioactivity in each fraction was counted (16, 35).
Effects on FGF-2 displacement and mitogenic activity
Release of ECM-bound 125FGF-2 and stimulation of FGF-2
mitogenic activity were performed, as described (16, 35).
Selectin inhibitory activity
The ability of heparin and heparin derivatives to inhibit
adhesion of LS180 cells to immobilized P- and L-selectin was
examined as described previously (17). Briefly, ELISA plates
(Nunc, Rochester, NY, USA) coated overnight with soluble
protein A were blocked with 1% BSA in HBSS (HBSS/BSA)
for 30 min at RT. Mouse P- and L-selectin chimeras (400
ng/well in HBSS/BSA) were incubated for 3 h at RT. After
three washes, calcein AM-labeled LS180 tumor cells (50,000
cells/well) were added to the plate in the presence or absence
of serially diluted heparin derivatives at concentrations rang-
ing from 0.24 g/ml to 250 g/ml. Plates were incubated for
1 h at 4°C while rotating on an Orbital Rotor at 70 rpm. Wells
were washed with HBSS/BSA and HBSS. Adherent cells were
lysed with 1% Triton X-100 and quantified by measuring the
fluorescence with a GENios ELISA reader (Tecan). The IC50
values were calculated from three independent experiments.
Bioavailability of heparin derivatives in the circulation
Wild-type mice (C57BL/6J) were i.v. injected with 300 g of
FITC-conjugated heparin derivatives in 120 l of PBS (either
RO.H or 100NA-RO.H) via the tail vein. Blood samples were
collected by retro-orbital bleeding at different time points.
Mice were euthanized at 2 h and blood was collected by
cardiac puncture. The anticoagulated blood was centrifuged
at 2000 g for 10 min. Plasma (80 l of the supernatant) was
transferred to an ELISA plate and fluorescence was measured
with a GENios ELISA reader (Tecan). Plasma from a mouse
receiving PBS only was used as a control.
Platelet/tumor cell aggregation in vivo
Lungs were analyzed at various time points after i.v. injection
of tumor cells by sectioning and staining as described previ-
ously (17). Frozen lung sections were incubated with anti-
CD41 Ab (Becton Dickinson), followed by detection with goat
anti-rat Ab conjugated with Alexa568 (Invitrogen). The ex-
tent of platelet/tumor cell association was quantified in 20
view fields (40 magnification) by immunofluorescence mi-
croscopy.
Experimental metastasis model
C57BL/6J mice were i.v. injected with 150 g of heparin
derivatives or PBS, followed by injection of 3 105 MC-38GFP
colon carcinoma cells or B16-BL6 melanoma cells via the tail
vein 10 min later. Mice injected with MC-38GFP cells were
euthanized after 4 wk and metastatic foci were counted on
dissected lungs. Lungs were homogenized and the GFP
fluorescence was measured (21). Mice injected with B16-BL6
melanoma cells were euthanized after 14 days and the meta-
static foci were counted. For the subcutaneous (s.c.) injec-
tion, 300 g of heparin derivatives was applied 30 min before
i.v. injection of B16-BL6 cells.
RESULTS
Selectin ligand expression and heparanase activity of
MC-38 and B16-BL6 cells
To determine the role of heparin during metastasis, we
analyzed two mouse cell lines, MC-38 colon carcinoma
and B16-BL6 melanoma cells, in which reduction of
metastasis has been shown to be achieved by inhibition
of either selectin-mediated interactions or heparanase
enzymatic activity, respectively. When selectin ligand
expression was compared by flow cytometry, both
MC-38 and B16-BL6 cells expressed P-selectin ligands
(Fig. 1A). P-selectin binding to B16-BL6 cells was less
efficient than to MC-38 cells. L-selectin ligands were
detected on both cells, but no binding of E-selectin
could be observed (Fig. 1A and ref. 21). Heparanase
activity expressed by both cell lines was determined by
analysis of sulfate-labeled material released from meta-
bolically labeled ECM (27). B16-BL6 cells exhibited
significant levels of heparanase activity, as detected by
the large amount of low molecular weight material
eluted in fractions 25–35 (Fig. 1B). Eluted labeled
fragments were shown to be degradation products of
heparan sulfate (HS), resistant to further digestion with
papain and chondroitinase ABC, and susceptible to
deamination by nitrous acid (16, 35). In contrast,
MC-38 cells exhibited relatively little heparanase activ-
ity, and the major sulfate-labeled product was of high
molecular weight eluted in fractions 5–10 (Fig. 1B).
This material provides a readily accessible soluble sub-
strate for the heparanase enzyme and is produced by
proteolytic enzymes degrading the proteoglycan core
protein and residing in the ECM and cell lysates (16).
We have previously demonstrated that degradation of
heparan sulfate proteoglycans in the ECM involves the
sequential action of proteases and heparanase and that
inhibition of heparanase is associated with a marked
accumulation of soluble, nearly intact proteoglycans
(16, 38). This was also the case for incubation of the
ECM with B16-BL6 melanoma cells in the presence of
RO.H or 100NA-RO.H (data not shown). Altogether, we
compared MC-38 cells, expressing primarily selectin
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ligands, with B16-BL6 cells expressing both selectin
ligands and heparanase activity.
Chemically modified heparin derivatives inhibit
selectins
A series of modified heparin derivatives of different
degrees of sulfation, N-acetylation, and chain flexibility,
including 2-O- and 6-O-desulfated, N-acetylated, and
“reduced oxyheparins” (RO heparins), was prepared
and analyzed for heparanase inhibitory activity (35).
RO derivatives are a form of “glycol-split” heparins
where the C(2)-C(3) bonds of all nonsulfated uronic
acid residues are cleaved, with retention of the original
chain length of heparins. Since glycol-split residues act
as flexible joints along the polysaccharide chains (35),
selected RO derivatives were inserted in this study
because they enabled us to evaluate the effect of chain
flexibility on the biological activities of interest. RO.H
has been shown to inhibit experimental metastasis (26,
39) and block P-selectin-mediated acute inflammation
(40). To identify heparin derivatives with selectin inhib-
itory activity, we tested 15 different compounds for
their potential to inhibit adhesion of LS180 carcinoma
cells to immobilized selectins (Supplemental Fig. 1).
The different heparin derivatives vary significantly in
their ability to inhibit selectins as determined by their
IC50 values (Table 1). Two heparin derivatives, 58%
N-acetylated heparin (58NA-H) and reduced oxyhepa-
rin (RO.H), had better P-selectin inhibitory activity
(IC50 20–25 g/ml) than unmodified, unfractionated
heparin (H). In addition, RO.H was the only derivative
that preserved L-selectin inhibitory potential compara-
ble to heparin (IC50 values of 45 and 40 g/ml,
respectively). In contrast, 100% N-acetylated reduced
oxyheparin (100NA-RO.H) was virtually inactive as an
inhibitor of both P- and L-selectin (IC50250 g/ml).
In general, N-desulfation (N-acetylated derivative), 2-O-
desulfation, and 50% glycol-splitting of heparin re-
sulted in a marked reduction of selectin inhibitory
activity (Table 1). The 6-O-sulfate was previously found
to be critical for selectin binding (41), and its removal
completely eliminated its recognition by selectins (Ta-
ble 1). However, a partial 6O- or N-desulfation (39–
70%), followed by N-acetylation, led to products still
endowed with potent selectin inhibitory properties
(IC50 values for P-selectin between 25 and 40 g/ml),
indicating that a certain de-O-sulfation did not inter-
fere with P-selectin recognition but eliminated interac-
tions with L-selectin. Based on the selectin binding
properties, two heparin derivatives with a good inhibi-
tory activity (58NA-H and RO.H) and one derivative
with no selectin-inhibitory activity (100NA-RO.H) were
selected for further study.
Heparin has a variety of biological activities that can
help explain its effects on cancer metastasis and angio-
genesis. Six of these activities were investigated in more
detail: 1) anticoagulant activity; 2) potential to release
tissue factor pathways inhibitor, TFPI; 3) inhibition of
selectin-mediated interactions (discussed above); 4)
inhibition of heparanase; 5) release of ECM bound
fibroblast growth factor (FGF-2); and 6) stimulation of
Figure 1. Characterization of selectin ligands and heparanase activity in mouse colon carcinoma MC-38 and melanoma B16-BL6
cell lines. A) Selectin ligands. Cells were probed with mouse P-selectin and L-selectin chimeras and analyzed by flow cytometry.
Filled areas (gray): selectin-stained cells; boldface line: selectin staining in the presence of 5 mM EDTA; thin line represents
control profiles with secondary antibody only. B) Heparanase activity. MC-38 cells and B16-BL6 melanoma cells were incubated
with sulfate-labeled ECM. Degradation fragments released into the incubation medium were separated by gel filtration on
Sepharose 6B as described in Materials and Methods. Fractions 25–35 corresponded to HS degradation fragments and material
eluted in fractions 5–10 corresponded to undigested HS proteoglycans.
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FGF-2 mitogenic activity (Table 2). We aimed to evalu-
ate the contribution of selectin-mediated interactions
and heparanase activity to the metastatic process. Hep-
arin derivatives were previously evaluated for their
potency to inhibit heparanase (35). Although 58NA-H
was a poor inhibitor of heparanase, RO.H and 100NA-
RO.H were both excellent inhibitors (Table 2 and (35).
These heparin derivatives were tested for their antico-
agulant activity in vivo. The anti-Xa activity was deter-
mined in plasma of mice i.v. injected with these heparin
derivatives (Table 2). All three derivatives were found
to be nonanticoagulant. N-Desulfation of heparin was
previously described to eliminate the binding sites for
antithrombin, thus consistently decreasing the antico-
agulant properties (41). When these heparin deriva-
tives were tested in normal mouse plasma ex vivo, the
anti-Xa levels were about half the values measured in
vivo (data not shown). These findings indicate that
there could be other factors contributing to anticoag-
ulation in vivo. Heparin is known to release tissue factor
pathway inhibitor (TFPI) from the vascular endothe-
lium, thereby increasing its plasma concentration sev-
eralfold (42–44). Whereas heparin injection increased
TFPI concentration in the plasma of a mouse 2-fold
over basal levels, two of the derivatives (RO.H, 100NA-
RO.H) were less efficient than heparin (Table 2). The
observed reduction in TFPI release was expected to be
associated with the loss of sulfation, which is important
for TFPI-heparin interactions (43). However, the TFPI
release observed for RO.H is significantly lower than for
H (Table 2) despite the same degree of sulfation.
Heparin can efficiently release growth factors seques-
tered in the extracellular matrix (ECM), thus mobiliz-
ing the pool of molecules capable of potentiating
tumor growth and metastasis (14, 16, 45). Compounds
58NA-H and RO.H exhibited FGF-2-releasing activity
comparable to heparin whereas 100NA-RO.H showed
limited efficacy (Table 2). Finally, stimulation of FGF-2
mitogenic activity by heparin derivatives showed that
100NA-RO.H has a reduced potential, and the other two
derivatives are similar to heparin. In conclusion, three
heparin derivatives were identified that possess rela-
tively little anticoagulant activity but are unique in their
selectin and heparanase inhibitory activity: 58NA-H as
TABLE 1. IC50 values of heparin derivatives for inhibition of selectins
Heparin and heparin derivatives
Inhibition of cell adhesion (IC50 , g/ml)
P-selectin l-selectin
Heparin (H) 40 35
2-O-desulfated H (iduron. acid form) (2Odes-H IdoA) 250 210
2-O-desulfated H (galact. acid form) (2Odes-H GalA) 110 250
6-O-desulfated H (6Odes-H) 250 500
6-O-desulf., partially 2-O-desulf. H (6Odes,p2Odes-H) 250 500
51% 6-O-desulfated H (516Odes-H) 30 100
42% 6-O-desulfated H (426Odes-H) 30 150
39% N-acetylated H (396Odes-H) 25 125
50% N-acetylated H (50NA-H) 35 125
58% N-acetylated H (58NA-H) 25 125
70% N-acetylated H (70NA-H) 40 200
100% N-acetylated H (100NA-H) 175 250
50% N-acetylated, 25% glycol-split H (50NA-RO.H) 27 75
100% N-acetylated, 25% glycol-split H (100NA-RO.H) 250 500
25% Glycol-split H (RO.H) 20 60
TABLE 2. Biological activities of heparin derivatives
Heparin derivatives
Anti-Xa activity
(units/ml)a
TFPI release
activity (%)b
Inhibition of
selectin-cell adhesion
(IC50 , g/ml) Heparanase
inhibitory
activity (%)c
FGF-2 release
from ECM (%)d
Stimulation of FGF-2
mitogenic activity (%)eP-selectin l-selectin
H 4 100 40 40 78.7 66.1 100
58NA-H 0.1 98.2 25 125 40.9 83.4 72.6
RO.H 0.05 72.8 20 45 95.4 84.5 83
100NA-RO.H 0.01 67.3 250 500 82.8 23.7 35.1
a The anticoagulant activity of heparin and its derivatives was determined in plasma samples taken from mice 10 min after injection of 150
g of the heparin derivative, as described in Materials and Methods. b Quantitation of TFPI release in the plasma of mice injected with 150 g
of a heparin derivative analyzed 10 min after the injection. Percentage of the activity of heparin. c Percent inhibition in the presence of a heparin
derivative (1 g/ml). d Percent release of ECM-bound FGF-2 in the presence of a heparin derivative (0.5 g/ml). 100%  total ECM-bound
FGF-2. e Percent stimulation of FGF-2-induced 3H-thymidine incorporation (BAF3 lymphoid cells) in the presence of a heparin derivative (0.5
g/ml). 100%  3H-thymidine incorporation in the presence of heparin.
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an inhibitor of P- and L-selectin and a poor heparanase
inhibitor; RO.H as a good inhibitor of P- and L-selectin
as well as of heparanase activity; and 100NA-RO.H as a
rather specific inhibitor of heparanase activity.
Pharmacokinetics of heparin derivatives in vivo
To determine an effective dose of heparin derivatives
for the metastasis experiments, we first analyzed the
bioavailability of the three heparin derivatives in vivo.
Fluorescein (FITC)-conjugated heparin derivatives
were i.v. injected and their plasma levels were deter-
mined. Derivatives 58NA-H and 100NA-RO.H had a
similar clearance from blood circulation, as reported
for unfractionated heparin (17) and observed for the
same heparin derivatives under different conditions
(s.c. injection at higher concentrations) in tumor-
bearing mice (C. Pisano, Sigma Tau, Italy, personal
communication). Heparin derivatives were rapidly re-
moved from blood circulation with an average half-life
of 30 min 	 10 min (Fig. 2A). Tumor cells carrying
selectin ligands are known to form tumor cell emboli
mediated primarily through platelet P-selectin (17, 46).
To test heparin derivatives for their efficiency in inhib-
iting platelet/tumor cell interactions, wt mice (C57BL/
6J) were i.v. injected with PBS or 150 g of P-selectin-
blocking heparin derivative, 58NA-H, followed by
injection of MC-38GFP cells 5 min later. Mice were
euthanized 30 min and 4 h postinjection, respectively.
About 80% of tumor cells in the lung tissue of PBS-
injected mice were associated with platelets (Fig. 2B).
58NA-H significantly reduced platelet/tumor cell em-
boli formation and was comparable to H. Furthermore,
reduced platelet adhesion to tumor cells was observed
after 4 h, but there was no difference in platelet/tumor
cell interactions at 8 h postinjection (data not shown).
These results indicate that the heparin derivative is
biologically active for at least 4 h post-tumor injection
despite its rapid clearing from the blood.
Selectin-specific heparin derivatives attenuate
metastasis of MC-38 cells
To determine the ability of the selected nonanticoagu-
lant heparin derivatives to attenuate metastasis, we i.v.
injected wt mice with 150 g of modified heparin,
followed by injection of MC-38GFP cells 10 min later.
Injection of unmodified heparin shortly before the
tumor cells was previously shown to affect primarily
P-selectin-mediated interactions (17, 22, 24). After 4 wk
mice were euthanized and metastases were evaluated by
counting of metastatic foci, followed by a detection of
GFP fluorescence in the lung homogenate (Fig. 3). In
mice receiving only PBS, lung tissues were displaced by
metastases. A marked reduction of metastases forma-
tion was noted in mice receiving either 58NA-H or
RO.H (Fig. 3A, B). Both the number of metastatic foci
(Fig. 3B), reflecting the initiation of metastasis, and the
GFP fluorescence of lung homogenates (Fig. 3A) re-
flecting the overall tumor burden were markedly re-
duced. The heparin derivatives have no effect on tumor
cell proliferation or viability in vitro (data not shown).
In contrast, the heparanase-specific inhibitor 100NA-
RO.H had no significant effect on lung colonization of
MC-38 cells. To test whether the observed attenuation
of metastasis was due to P-selectin inhibition, we tested
the effect of these heparin derivatives in P-selectin-
deficient mice (P-sel/). Again, the heparanase-
Figure 2. Bioavailability of heparin derivatives in vivo. Mice were i.v.
injected with FITC-conjugated heparin derivatives and analyzed as a
function of time. A) Blood samples were drawn at different time
points and the presence of heparin derivatives in the plasma was
detected by fluorescence measurement. Plasma from a mouse in-
jected with PBS was used as control. B) Platelet adhesion to i.v.-
injected MC-38GFP cells was analyzed in mice receiving a heparin
derivative and compared with PBS and heparin-injected mice. The
number of platelet/positive tumor cells in the lungs of mice eutha-
nized at 30 min and 4 h after injection were counted as described in
Materials and Methods. The difference in platelet/tumor cell associ-
ation between control-injected mouse (PBS) and heparin-injected
mice was found to be statistically significant by an ANOVA test
(P0.01). C) Representative photomicrographs of platelet tumor cell adhesion in lungs of mice injected with either
58NA-H or PBS and euthanized 30 min later. Bar  100 m; inset bar  50 m.
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specific inhibitor 100NA-RO.H did not affect metastasis.
The number of metastatic foci was reduced by injec-
tion of the 58NA-H or RO.H derivatives (Fig. 3C).
These derivatives effectively inhibited L-selectin
binding but differed in other parameters (Table 2).
We showed previously that heparin is an efficient
inhibitor of L-selectin-mediated interactions that oc-
cur subsequent to P-selectin-mediated platelet/tu-
mor cell interactions (32). To exclude any possible
involvement of L-selectin inhibition, we tested the
antimetastatic effect of 58NA-H in mice deficient in
both P- and L-selectin (PL-sel/ mice). Notably,
no further attenuation of metastasis could be de-
tected (Fig. 3D). Taken together, these data show
that in the MC-38 cell system 58NA-H affected primar-
ily P-selectin-mediated interactions, and possibly also
L-selectin. The complete inability of the heparanase-
specific heparin derivative 100NA-RO.H to affect me-
tastasis of MC-38 cells correlates with the lack of
heparanase activity in these cells.
Equal efficiency of selectin and heparanase inhibition
to attenuate metastasis
To compare the respective contribution of heparanase
and selectin-mediated interactions with metastasis, we
tested the effect of heparin and its derivatives on lung
colonization of B16-BL6 melanoma cells producing
both P-selectin ligands and heparanase (Fig. 1). Intra-
venous injection of mice with 150 g of heparin or
heparin derivatives, followed by injection of B16-BL6
cells, led to a significant attenuation of metastasis (Fig.
4A, B). The heparanase-specific derivative 100NA-RO.H
reduced metastasis, albeit to a lesser extent than hepa-
rin (Fig. 4A). Notably, the selectin-specific inhibitor
58NA-H was as efficient an inhibitor of metastasis as
100NA-RO.H. To determine whether these two activities
act synergistically during the initiation phase of exper-
imental metastasis, we tested the heparin derivative
RO.H, which exerts both selectin and heparanase in-
hibitory activities. However, the extent of metastases
reduction achieved by RO.H was comparable to that of
the other derivatives, indicating no synergy (Fig. 4A).
Finally, we compared the efficacy of heparin derivatives
delivered by either i.v. or s.c. injection. Despite limited
data about pharmacokinetics of heparin in a mouse
model, s.c. injection of unfractionated heparin was
shown to attenuate metastasis (24, 26, 39). Mice were
injected with 300 g of selectin-specific 58NA-H and
heparanase-specific 100NA-RO.H derivatives, followed
by injection of B16-BL6 melanoma cells 30 min later
(Fig. 4C). Attenuation of metastasis with an i.v. injec-
tion of 300 g was comparable to the 150 g dose for
both derivatives (Fig. 4A). However, s.c. injection of
58NA-H further reduced metastasis compared with i.v.
delivery. There was no difference in the antimetastatic
effect of 100NA-RO.H regardless of the type of injection.
Taken together, inhibition of selectin-mediated in-
teractions affects adhesion processes whereas targeting
heparanase affects enzymatic degradation of the tumor
cell microenvironment. The lack of synergy between
these two mechanisms in the B16-BL6 melanoma
model might indicate that both mechanisms occur
concomitantly, affecting closely associated events in the
metastatic process.
Figure 3. Heparin derivatives devoid of anticoagulant activity attenuate
metastasis of MC-38 cells primarily through selectin inhibition. Mice were i.v.
injected with 150 g of heparin derivatives 10 min before injection of 3  105
MC-38GFP cells. A–C) Mice were injected with PBS, 58NA-H, RO.H, and
100NA-RO.H. A) The extent of lung colonization was analyzed by GFP
fluorescence read out in lung homogenates of wt mice 28 days after injection.
B) Metastatic foci counts in wt mice. C) Metastatic foci count in P-sel/
mice 35 days after MC-38GFP cell inoculation. A 2-way ANOVA multiple
comparison test was used to determine the statistical significance of 58NA-H
and RO.H vs. controls for panels A–C (P0.01). There is no difference
between control and 100NA-RO.H-injected mice for panels A–C (P0.15). D)
PL-selectin double deficient mice (PL-sel/) were injected with 58NA-H or
PBS. Mice were euthanized after 35 days and lungs were evaluated for metastatic foci. The difference was not
statistically significant (P0.48).
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DISCUSSION
Numerous studies suggest that heparin and LMWH
affect cancer progression in humans (10, 47). In addi-
tion, there is increasing experimental evidence suggest-
ing that heparin is an inhibitor of metastasis in various
mouse and rat models (19). Due to the known relation-
ship between cancer and thrombosis, heparin and
LMWH are commonly used primarily as anticoagulants
in the treatment of cancer patients suffering from
thrombosis (10, 20). The ability of heparin to affect the
coagulation pathway led to the assumption that heparin
reduces metastasis through its antithrombotic activity.
Experimental evidence, however, indicated that hepa-
rin derivatives with no anticoagulant activity reduce
metastasis in mice (16, 23, 25, 26). Here, we address the
issue of other biological activities of heparin that could
potentially affect metastasis focusing on the involve-
ment of selectins and heparanase. The currently char-
acterized heparin derivatives, with virtually no antico-
agulant activity, allowed us to identify heparin
preparations specific for the inhibition of selectins,
58NA-H, heparanase, 100NA-RO.H, or both activities,
RO.H. The negligible anticoagulant activity of 58NA-H,
RO.H, and 100NA-RO.H as expressed by their anti-Xa
activity (Table 2) rules out any contribution of anti-
thrombin-mediated activities to the antimetastatic activ-
ity of these heparin derivatives. On the other hand,
anticoagulant properties can be contributed by release
of TFPI, at least for 58NA-H and RO.H (Table 2). Such
an activity is surprisingly high for 58NA-H, which is
almost as active a TFPI releaser as heparin despite its
consistently lower degree of sulfation due to replace-
ment of more than half of the original N-SO3 groups. It
is possible that, for TFPI release, only half of N-sulfate
groups on heparin are sufficient, similar to heparanase
inhibition (35). The lower TFPI-releasing activity of
RO.H compared with heparin (Table 2) suggests that
other structural features, in addition to charge, affect
its activity.
The selectin-specific heparin derivative 58NA-H was
an efficient inhibitor of metastasis in two syngeneic
murine models. The attenuation of metastasis observed
in the MC-38 carcinoma model was comparable to the
effect of unfractionated heparin (17). Unlike the al-
most complete reduction of metastatic foci lesions
(5–6/lung) achieved with MC-38 cells, only a partial
(60%) inhibition of lung colonization was observed
with B16-BL6 melanoma cells (100 foci/lung). How-
ever, P-selectin binding to melanoma cells is low and
correlates with the limited amount of selectin ligands
on the cell surface (48). This is in contrast to abundant
selectin ligand expression in most carcinomas (49).
This opens up a possibility that heparin derivatives
could also inhibit interactions of selectins with endog-
enous ligands (e.g., P-selectin binding to PSGL-1). This
is supported by recent findings that endogenous selec-
tin ligands, as determined by fucosyltransferase-7 activ-
ity, are required for metastatic progression (32). De-
spite the different nature of both tumor cells, targeted
inhibition of P-selectin with 58NA-H markedly reduced
metastasis, in agreement with previous observations
obtained in P-selectin-deficient mice (21, 22). The fact
that 58NA-H further attenuated lung colonization of
MC-38 cells even in P-sel/ mice pointed toward an
Figure 4. Experimental metastasis of B16-BL6 melanoma cells is efficiently attenuated by heparin derivatives with selectin
and/or heparanase inhibitory activity. A) Wt mice were i.v. injected with 150 g of heparin derivatives 10 min before injection
of 3  105 of B16-BL6 melanoma cells. Fourteen days after injection mice were euthanized, and the lungs were dissected and
evaluated for metastatic foci. Statistical significance was determined by a 2-way ANOVA multiple comparison test, where all
treatments were compared with the controls or heparin treatment (P0.001). There was no statistical difference among
treatments with heparin derivatives (P0.7). B) Representative images of lungs injected with 58NA-H or PBS. C) Wt mice were
injected with 300 g of heparin derivatives either i.v. or s.c. 30 min before injection of 3  105 B16-BL6 melanoma cells. After
13 days, mice were euthanized and the lungs were dissected and evaluated for metastatic foci. Statistical significance was
determined by a 2-way ANOVA multiple comparison test, where all treatments were compared with the controls or heparin
treatment (P0.001). Treatment with 58NA-H was found to be statistically different between s.c. and i.v. delivery (P0.001).
There was no statistical difference between i.v. and s.c. delivery of 100NA-RO.H (P0.5).
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additional biological activity. No further effect could be
observed in PL-sel/ mice (Fig. 3D). It could be
argued that the dramatic reduction of MC-38 metastasis
in PL-sel/ mice (just a few metastatic foci per lung)
makes it virtually impossible to detect a further de-
crease. Yet a considerable amount of B16-BL6 meta-
static foci was detected in PL-sel/ mice (data not
shown). If additional biological activities carried out by
heparin derivatives would be involved, their further
effect should have been detectable. Hence, these find-
ings suggest that the potential of heparin to attenuate
metastasis is mediated primarily through inhibition of
selectin-mediated interactions.
Heparanase inhibition with 100NA-RO.H did not
affect metastasis of MC-38 carcinoma cells in either wt
or P-sel/ mice (Fig. 3A, B). However, 100NA-RO.H
could efficiently attenuate metastasis of B16-BL6 mela-
noma cells (Fig. 4A). Together with the finding of a
virtual absence of heparanase expression in MC-38
cells, these data imply that tumor cell-derived hepara-
nase is required for metastatic progression in mela-
noma (16, 50). Tumor cell invasiveness and extracellu-
lar matrix degradation require the expression of
heparanase at specific sites in close vicinity of the cells
(29). Extracellular proteases are produced by inflam-
matory cells, stromal cells, and/or the tumor cells
themselves. Tumor cell emboli formation is associated
with adhesion of platelets and leukocytes to tumor cells
(51). Since platelets and leukocytes produce significant
amounts of heparanase, their contribution to metasta-
sis would be anticipated (52, 53). Our results suggest
that the heparanase available from the metastatic mi-
croenvironment of the tumor cell does not contribute
significantly to metastatic initiation. The inhibition of
heparanase by modified heparins was shown previously
to attenuate experimental metastasis only in a defined
time period, either shortly before tumor cell injection
or up to 3 h after the injection of tumor cells (16).
Modified heparins capable of heparanase inhibition
were also found to be good inhibitors of selectins (L.
Borsig, unpublished observations, 1999). Taken to-
gether, these results indicate that heparanase activity
expressed specifically by the tumor cells is essential for
metastasis.
The use of experimental metastasis mouse models
allowed us to study the effect of heparin in a time-
dependent manner. Heparin derivatives were shown to
stay biologically active in vivo for 4 h after a single
injection, as determined by reduction of platelet/
tumor cell adhesion (Fig. 2). This narrow time frame
for the action of heparin derivatives restricts their
potential effects on the early step of metastatic coloni-
zation. Since selectins are known to initiate the first
steps of cell-cell interactions (30, 31), the inhibition of
selectin-mediated interactions probably belongs to one
of the earliest actions associated with metastasis (17,
18). The availability of heparin or its derivatives during
this short time frame makes any subsequent activities of
heparin (e.g., inhibition of angiogenesis) unlikely. The
observed inhibition of platelet-tumor cells aggregate
formation after administration of 58NA-H signifies the
involvement of P-selectin in this process (17, 46).
Formation of platelet/tumor cell aggregates is associ-
ated with cancer progression, but the precise molecular
mechanism remains to be determined (51). Platelets
were shown not only to protect the tumor cells from the
innate immune response and/or promote their reten-
tion in the vascular bed, but also to facilitate extravasa-
tion of tumor cells that have been attached to the
vascular endothelium (54). Our observations arising
from a direct comparison of selectin inhibitory and
heparanase inhibitory heparin derivatives support the
primary involvement of selectins during metastasis ini-
tiation. The efficiency of heparanase inhibition ob-
served upon attenuation of B16-BL6 melanoma and
breast carcinoma metastasis (16, 27, 50) demonstrates
the relevance of heparanase in these tumor cells. Since
no synergy between simultaneous inhibition of hepara-
nase and selectins by the RO.H derivative could be
detected, both mechanisms are likely to act in the same
time period. When compared with any of the heparin
derivatives, the higher efficiency of H to attenuate
metastasis of B16-BL6 cells shows the different biology
of melanomas and carcinomas while suggesting that
other biological activities could be responsible for the
observed additional efficiency in melanomas. Notably,
s.c. delivery of 58NA-H derivative reduced metastasis to
similar levels as H (Fig. 4). These findings indicate that
the presumably prolonged delivery of 58NA-H affected
other biological activities, possibly also L-selectin.
Among the three investigated heparin derivatives,
58NA-H possesses biological activities quite similar to H,
whereas 100NA-RO.H contains only heparanase inhibi-
tory activity (Table 2). Nevertheless, a single treatment
with these heparin derivatives leads to a considerable
attenuation of metastasis, which underlines the impor-
tance of interfering with the initiation phase of this
process.
The study of heparin derivatives during metastasis
further delineates the underlying mechanism involved
in this process. Even though a complete dissection of all
individual biological activities of heparin is unlikely to
be achieved, a better understanding of this process will
help to design specific inhibitors targeting cancer pro-
gression. Further characterization of heparin biology in
the context of cancer is indisputably necessary. Nev-
ertheless, by modulating many biological functions
(e.g., coagulation, heparanase, angiogenesis, selectins,
growth factors, etc.), the effects of heparin and LMWH
on cancer progression that have already been described
would also make heparin therapy beneficial for cancer
patients (18). The extensive experience with heparin
and LMWH therapy for thrombotic indications pro-
vides a rationale for cancer treatment. Since there is no
treatment currently available for metastasis, LMWH
and its modified species could be used as the first
feasible treatment of metastasis progression.
We thank Claudia Ruedin for technical assistance and Dr.
Eric G. Berger and Dr. G. Cassinelli for critical reading of the
3570 Vol. 21 November 2007 HOSTETTLER ET AL.The FASEB Journal
manuscript. This work was supported by Swiss National Foun-
dation grant #3100A0–100303 (to L.B.) and in part by the
European Commission (Contract QLK3-CT-2002–02049)
and the US-Israel Binational Science Foundation (#2003261).
REFERENCES
1. Lazo-Langner, A., Goss, G. D., Spaans, J. N., and Rodger, M. A.
(2007) The effect of low-molecular-weight heparin on cancer
survival. A systematic review and meta-analysis of randomized
trials. J. Thromb. Haemost. 5, 729–737
2. Zacharski, L. R., Ornstein, D. L., and Mamourian, A. C. (2000)
Low-molecular-weight heparin and cancer. Semin. Thromb. He-
most. 26. Suppl. 1, 69–77
3. Smorenburg, S. M., Hettiarachchi, R. J., Vink, R., and Buller,
H. R. (1999) The effects of unfractionated heparin on survival
in patients with malignancy—a systematic review. Thromb. Hae-
most. 82, 1600–1604
4. Cosgrove, R. H., Zacharski, L. R., Racine, E., and Andersen, J. C.
(2002) Improved cancer mortality with low-molecular-weight
heparin treatment: a review of the evidence. Semin. Thromb.
Hemost. 28, 79–88
5. Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low,
V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., and
Williamson, R. C. (2004) Low molecular weight heparin, ther-
apy with dalteparin, and survival in advanced cancer: the
fragmin advanced malignancy outcome study (FAMOUS).
J. Clin. Oncol. 22, 1944–1948
6. Lee, A. Y., Rickles, F. R., Julian, J. A., Gent, M., Baker, R. I.,
Bowden, C., Kakkar, A. K., Prins, M., and Levine, M. N. (2005)
Randomized comparison of low molecular weight heparin and
coumarin derivatives on the survival of patients with cancer and
venous thromboembolism. J. Clin. Oncol. 23, 2123–2129
7. Lee, A. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K.,
Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., and
Gent, M. (2003) Low-molecular-weight heparin versus a couma-
rin for the prevention of recurrent venous thromboembolism in
patients with cancer. N. Engl. J. Med. 349, 146–153
8. Klerk, C. P., Smorenburg, S. M., Otten, H. M., Lensing, A. W.,
Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M., Richel, D. J.,
van Tienhoven, G., and Buller, H. R. (2005) The effect of low
molecular weight heparin on survival in patients with advanced
malignancy. J. Clin. Oncol. 23, 2130–2135
9. Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A.,
Cetin, M., and Soyuer, S. (2004) A randomized clinical trial of
combination chemotherapy with and without low-molecular-
weight heparin in small cell lung cancer. J. Thromb. Haemost. 2,
1266–1271
10. Rickles, F. R. (2006) Mechanisms of cancer-induced thrombosis
in cancer. Pathophysiol. Haemost. Thromb. 35, 103–110
11. Lever, R., and Page, C. P. (2002) Novel drug development
opportunities for heparin. Nat. Rev. Drug. Discov. 1, 140–148
12. Hettiarachchi, R. J., Smorenburg, S. M., Ginsberg, J., Levine, M.,
Prins, M. H., and Buller, H. R. (1999) Do heparins do more
than just treat thrombosis? The influence of heparins on cancer
spread. Thromb. Haemost. 82, 947–952
13. Mousa, S. A. (2002) Anticoagulants in thrombosis and cancer:
the missing link. Semin. Thromb. Hemost. 28, 45–52
14. Jayson, G. C., and Gallagher, J. T. (1997) Heparin oligosaccha-
rides: inhibitors of the biological activity of bFGF on Caco-2
cells. Br. J. Cancer 75, 9–16
15. Mousa, S. A., and Mohamed, S. (2004) Inhibition of endothelial
cell tube formation by the low molecular weight heparin,
tinzaparin, is mediated by tissue factor pathway inhibitor.
Thromb. Haemost. 92, 627–633
16. Vlodavsky, I., Mohsen, M., Lider, O., Svahn, C. M., Ekre, H. P.,
Vigoda, M., Ishai-Michaeli, R., and Peretz, T. (1994) Inhibition
of tumor metastasis by heparanase inhibiting species of heparin.
Invasion Metastasis 14, 290–302
17. Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M.,
and Varki, A. (2001) Heparin and cancer revisited: mechanistic
connections involving platelets, P-selectin, carcinoma mucins,
and tumor metastasis. Proc. Natl. Acad. Sci. U. S. A. 98, 3352–
3357
18. Varki, N. M., and Varki, A. (2002) Heparin inhibition of
selectin-mediated interactions during the hematogenous phase
of carcinoma metastasis: rationale for clinical studies in humans.
Semin. Thromb. Hemost. 28, 53–66
19. Smorenburg, S. M., and Van Noorden, C. J. (2001) The
complex effects of heparins on cancer progression and metas-
tasis in experimental studies. Pharmacol. Rev. 53, 93–105
20. Zacharski, L. R. (2002) Anticoagulants in cancer treatment:
malignancy as a solid phase coagulopathy. Cancer Lett. 186, 1–9
21. Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., and Varki, A.
(2002) Synergistic effects of L- and P-selectin in facilitating
tumor metastasis can involve non-mucin ligands and implicate
leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci.
U. S. A. 99, 2193–2198
22. Ludwig, R. J., Boehme, B., Podda, M., Henschler, R., Jager, E.,
Tandi, C., Boehncke, W. H., Zollner, T. M., Kaufmann, R., and
Gille, J. (2004) Endothelial P-selectin as a target of heparin
action in experimental melanoma lung metastasis. Cancer Res.
64, 2743–2750
23. Kragh, M., Binderup, L., Vig Hjarnaa, P. J., Bramm, E., Johan-
sen, K. B., and Frimundt Petersen, C. (2005) Non-anti-coagulant
heparin inhibits metastasis but not primary tumor growth.
Oncol. Rep. 14, 99–104
24. Stevenson, J. L., Choi, S. H., and Varki, A. (2005) Differential
metastasis inhibition by clinically relevant levels of heparins—
correlation with selectin inhibition, not antithrombotic activity.
Clin. Cancer Res. 11, 7003–7011
25. Ono, K., Ishihara, M., Ishikawa, K., Ozeki, Y., Deguchi, H., Sato,
M., Hashimoto, H., Saito, Y., Yura, H., Kurita, A., and Maehara,
T. (2002) Periodate-treated, non-anticoagulant heparin-carry-
ing polystyrene (NAC-HCPS) affects angiogenesis and inhibits
subcutaneous induced tumour growth and metastasis to the
lung. Br. J. Cancer 86, 1803–1812
26. Yoshitomi, Y., Nakanishi, H., Kusano, Y., Munesue, S., Oguri, K.,
Tatematsu, M., Yamashina, I., and Okayama, M. (2004) Inhibi-
tion of experimental lung metastases of Lewis lung carcinoma
cells by chemically modified heparin with reduced anticoagu-
lant activity. Cancer Lett. 207, 165–174
27. Edovitsky, E., Elkin, M., Zcharia, E., Peretz, T., and Vlodavsky, I.
(2004) Heparanase gene silencing, tumor invasiveness, angio-
genesis, and metastasis. J. Natl. Cancer Inst. 96, 1219–1230
28. Cohen, I., Pappo, O., Elkin, M., San, T., Bar-Shavit, R., Hazan,
R., Peretz, T., Vlodavsky, I., and Abramovitch, R. (2006) Hepara-
nase promotes growth, angiogenesis and survival of primary
breast tumors. Int. J. Cancer 118, 1609–1617
29. Vlodavsky, I., Abboud-Jarrous, G., Elkin, M., Naggi, A., Casu, B.,
Sasisekharan, R., and Ilan, N. (2006) The impact of heparanase
and heparin on cancer metastasis and angiogenesis. Pathophysiol.
Haemost. Thromb. 35, 116–127
30. Ley, K. (2003) The role of selectins in inflammation and
disease. Trends. Mol. Med. 9, 263–268
31. Lowe, J. B. (2003) Glycan-dependent leukocyte adhesion and
recruitment in inflammation. Curr. Opin. Cell Biol. 15, 531–538
32. Laubli, H., Stevenson, J. L., Varki, A., Varki, N. M., and Borsig,
L. (2006) L-selectin facilitation of metastasis involves temporal
induction of fut7-dependent ligands at sites of tumor cell arrest.
Cancer Res. 66, 1536–1542
33. Koenig, A., Norgard-Sumnicht, K., Linhardt, R., and Varki, A.
(1998) Differential interactions of heparin and heparan sulfate
glycosaminoglycans with the selectins. Implications for the use
of unfractionated and low molecular weight heparins as thera-
peutic agents. J. Clin. Invest. 101, 877–889
34. Zacharski, L. R., and Ornstein, D. L. (1998) Heparin and
cancer. Thromb. Haemost. 80, 10–23
35. Naggi, A., Casu, B., Perez, M., Torri, G., Cassinelli, G., Penco, S.,
Pisano, C., Giannini, G., Ishai-Michaeli, R., and Vlodavsky, I.
(2005) Modulation of the heparanase-inhibiting activity of
heparin through selective desulfation, graded N-acetylation,
and glycol splitting. J. Biol. Chem. 280, 12103–12113
36. Nagasawa, K., and Uchiyama, H. (1978) Preparation and prop-
erties of biologically active fluorescent heparins. Biochim. Bio-
phys. Acta 544, 430–440
37. Singh, R., Pan, S., Mueske, C. S., Witt, T., Kleppe, L. S.,
Peterson, T. E., Slobodova, A., Chang, J. Y., Caplice, N. M., and
Simari, R. D. (2001) Role for tissue factor pathway in murine
model of vascular remodeling. Circ. Res. 89, 71–76
3571ANTI-METASTATIC ACTIVITY OF NON-ANTICOAGULANT HEPARIN
38. Bar-Ner, M., Kramer, M. D., Schirrmacher, V., Ishai-Michaeli, R.,
Fuks, Z., and Vlodavsky, I. (1985) Sequential degradation of
heparan sulfate in the subendothelial extracellular matrix by
highly metastatic lymphoma cells. Int. J. Cancer 35, 483–491
39. Lapierre, F., Holme, K., Lam, L., Tressler, R. J., Storm, N., Wee,
J., Stack, R. J., Castellot, J., and Tyrrell, D. J. (1996) Chemical
modifications of heparin that diminish its anticoagulant but
preserve its heparanase-inhibitory, angiostatic, anti-tumor and
anti-metastatic properties. Glycobiology 6, 355–366
40. Gao, Y., Li, N., Fei, R., Chen, Z., Zheng, S., and Zeng, X. (2005)
P-Selectin-mediated acute inflammation can be blocked by
chemically modified heparin, RO-heparin. Mol. Cells 19, 350–
355
41. Wang, L., Brown, J. R., Varki, A., and Esko, J. D. (2002)
Heparin’s anti-inflammatory effects require glucosamine 6-O-
sulfation and are mediated by blockade of L- and P-selectins.
J. Clin. Invest. 110, 127–136
42. Tobu, M., Ma, Q., Iqbal, O., Schultz, C., Jeske, W., Hoppen-
steadt, D. A., and Fareed, J. (2005) Comparative tissue factor
pathway inhibitor release potential of heparins. Clin. Appl.
Thromb. Hemost. 11, 37–47
43. Valentin, S., Larnkjer, A., Ostergaard, P., Nielsen, J. I., and
Nordfang, O. (1994) Characterization of the binding between
tissue factor pathway inhibitor and glycosaminoglycans. Thromb.
Res. 75, 173–183
44. Alban, S. (2001) Molecular weight-dependent influence of
heparin on the form of tissue factor pathway inhibitor circulat-
ing in plasma. Semin. Thromb. Hemost. 27, 503–511
45. Elkin, M., Ilan, N., Ishai-Michaeli, R., Friedmann, Y., Papo, O.,
Pecker, I., and Vlodavsky, I. (2001) Heparanase as mediator of
angiogenesis: mode of action. FASEB J. 15, 1661–1663
46. Kim, Y. J., Borsig, L., Varki, N. M., and Varki, A. (1998)
P-selectin deficiency attenuates tumor growth and metastasis.
Proc. Natl. Acad. Sci. U. S. A. 95, 9325–9330
47. Mousa, S. A. (2004) Low-molecular-weight heparin in thrombo-
sis and cancer. Semin. Thromb. Hemost. 30. Suppl. 1, 25–30
48. Ohyama, C., Tsuboi, S., and Fukuda, M. (1999) Dual roles of
sialyl Lewis X oligosaccharides in tumor metastasis and rejection
by natural killer cells. EMBO J. 18, 1516–1525
49. Mannori, G., Crottet, P., Cecconi, O., Hanasaki, K., Aruffo, A.,
Nelson, R. M., Varki, A., and Bevilacqua, M. P. (1995) Differen-
tial colon cancer cell adhesion to E-, P-, and L-selectin: role of
mucin-type glycoproteins. Cancer Res. 55, 4425–4431
50. Parish, C. R., Freeman, C., Brown, K. J., Francis, D. J., and
Cowden, W. B. (1999) Identification of sulfated oligosaccharide-
based inhibitors of tumor growth and metastasis using novel in
vitro assays for angiogenesis and heparanase activity. Cancer Res.
59, 3433–3441
51. Honn, K. V., Tang, D. G., and Crissman, J. D. (1992) Platelets
and cancer metastasis: a causal relationship? Cancer Metastasis.
Rev. 11, 325–351
52. Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R.,
Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I.,
Spector, L., and Pecker, I. (1999) Mammalian heparanase: gene
cloning, expression and function in tumor progression and
metastasis. Nat. Med. 5, 793–802
53. Hulett, M. D., Freeman, C., Hamdorf, B. J., Baker, R. T., Harris,
M. J., and Parish, C. R. (1999) Cloning of mammalian hepara-
nase, an important enzyme in tumor invasion and metastasis.
Nat. Med. 5, 803–809
54. Im, J. H., Fu, W., Wang, H., Bhatia, S. K., Hammer, D. A.,
Kowalska, M. A., and Muschel, R. J. (2004) Coagulation facili-
tates tumor cell spreading in the pulmonary vasculature during
early metastatic colony formation. Cancer Res. 64, 8613–8619
Received for publication February 24, 2007.
Accepted for publication May 10, 2007.
3572 Vol. 21 November 2007 HOSTETTLER ET AL.The FASEB Journal
